Adaptive Biotechnologies Corp ADPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Trading Information
- Previous Close Price
- $26.83
- Day Range
- $26.61–28.20
- 52-Week Range
- $12.01–30.68
- Bid/Ask
- $26.61 / $26.65
- Shares Outstanding
- 161.88M
- Market Cap
- $4.39B
- Volume/Avg
- 964,316 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 14.16
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 624
Valuation
Metric | ADPT |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 24.60 |
Price/Sales | 14.16 |
Price/Cash Flow | 343.86 |
Price/Earnings
ADPT
Financial Strength
Metric | ADPT |
|---|---|
Quick Ratio | 3.69 |
Current Ratio | 3.97 |
Interest Coverage | −7.96 |
Quick Ratio
ADPT
Profitability
Metric | ADPT |
|---|---|
Return on Assets (Normalized) | −0.09% |
Return on Equity (Normalized) | −0.26% |
Return on Invested Capital (Normalized) | −0.42% |
Return on Assets
ADPT
Diagnostics & Research Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | LOCK|$f<JDm$d | LOCK|&bb | $251B | |||
| Danaher Corp DHR | LOCK|$h#?xf% | LOCK|v>@ | $159B | |||
| IDEXX Laboratories Inc IDXX | LOCK|bP!zyJC | LOCK|YkL | $53B | |||
| Agilent Technologies Inc A | LOCK|%sTN^@Kl | LOCK|HfC | $48B | |||
| Waters Corp WAT | LOCK|q%@YV>> | LOCK|p> | $44B | |||
| IQVIA Holdings Inc IQV | LOCK|KWJ@hC> | LOCK|Dndt | $44B | |||
| Mettler-Toledo International Inc MTD | LOCK|>&@Mvpv | LOCK|nvk$ | $34B | |||
| Illumina Inc ILMN | LOCK|zcwZ@# | LOCK|&dPp | $31B | |||
| Labcorp Holdings Inc LH | LOCK|$KC%hyN | LOCK|%N>@r | $29B | |||
| Quest Diagnostics Inc DGX | LOCK|@<<&y^V | LOCK|y>@v | $28B |
United States